A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.

"Declaration of interest A.V. Soerensen has received travel grants to conferences and research grants from Pfizer and Novartis. F. Donskov has received research grants from the research fund of central Denmark Region, Novartis and GSK. R. Sandin is an employee at Pfizer and has stockownership in Pfizer. All remaining authors have no conflict of interest."

"This work was supported by Pfizer; Axel Muusfeldts fund; Christian Larsen and judge Ellen Larsens fund; Else and Mogens Wedell-Wedellsborgs Fund; Timber merchant Johannes Fogs Fund; Svend H.A. Schroeder and wife Ketty K. Larsen Fund; Novartis grant and the Department of Oncology and Research Fund at Herlev University Hospital. Results of this study were presented at the 2014 ESMO conference September 26–30, 2014, Madrid, Spain (poster presentation). Declaration of interestA.V. Soerensen has received travel grants to conferences and research grants from Pfizer and Novartis. F. Donskov has received research grants from the research fund of central Denmark Region, Novartis and GSK. R. Sandin is an employee at Pfizer and has stockownership in Pfizer. All remaining authors have no conflict of interest."

"The study was approved by the Danish Health Authorities, the Danish Research Ethics Committee and the Danish Data Protection Agency. The study was registered with ClinicalTrials.gov NCT01339962."